Bevacizumab versus Ranibizumab on As-Needed Treatment Regimen for Neovascular Age-Related Macular Degeneration in Turkish Patients

Table 1

General characteristics of the patients.

	Bevacizumab group	Ranibizumab group	P value
Mean age, years	71.4±8.2	73.8±7.2	0.1
Gender (male/female)	36/43	42/32	0.2
Laterality (right/left eye)	38/41	34/40	0.8
Follow-up time (months)	18.9±4.5	18.3±4.7	0.4
Lens status (phakic/pseudophakic)	59/19	47/27	0.1
CNV type (classic/occult)	23/56	20/54	0.8

CNV: choroidal neovascularization.